Answers are grounded in this paper and cite their sources.
Angiogenesis regulation is associated with disorders such as rheumatoid arthritis, diabetes, atherosclerosis, and cancer. Tumor development and metastasis are directly affected by tumor angiogenesis. In addition to tumor cells, host cells produce pro- and anti-angiogenic molecules that regulate tumor angiogenesis. VEGFs and their receptor, VEGFR2 (KDR), strongly influence angiogenesis. When activated, KDR undergoes autophosphorylation, which ultimately promotes endothelial cell proliferation, tumor angiogenesis, tumor growth, and metastasis. Overexpression of VEGFR2 has been observed in various cancer types, including hepatocellular carcinoma, renal carcinoma, non-small cell lung cancer, breast cancer, and cervical cancer. Researchers have developed several VEGFR2 inhibitors over the past few decades. This review examines the structure-activity relationships (SARs) of several recently developed chemical classes, including chalcones, quinazolines, pyridines, pyrimidines, thiadiazoles, indazoles, triazoles, quinoxalines, and pyrazoles, as VEGFR2 inhibitors, with an emphasis on anticancer activity. We also analyze the chemico-biological interaction profiles of several small-molecule VEGFR2 inhibitors. This review article provides an overview of the latest advances in medicinal chemistry approaches to VEGFR2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Bhagat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: